Abstract 85P
Background
Modulation of progesterone receptor (PR) expression and its functional crosstalk with estrogen receptor (ER), represent a potential approach for enhancing the response to hormonal therapy in breast cancer. Aberrant epigenetic alterations induced by histone deacetylases (HDACs) were massively implicated in dysregulating the function of hormone receptors. However, pan-HDAC inhibitors have shown limited clinical sucess due to the lack of efficacy and serious side effects. Therefore, targeting specific HDACs, like HDAC6, with isoform-selective inhibitors may enhance therapeutic outcomes to anti-hormonal drugs. Despite many reports demonstrating HDAC6's role in breast tumorgenesis, its contribution to hormone receptors regulation remains poorly undertstood. Here we set out to explore the role of HDAC6 in modulating PR expression and its impact on the response to hormonal therapy.
Methods
The correlation between HDAC6 and hormone receptors was investigated in patients’ tissues by immunohistochemistry (n=80) and publicly available data (n=3260) from breast cancer patients. We explored the effect of HDAC6 downregulation or overexpression as well as its catalytic inhibition in hormone receptor-positive and triple-negative cells. The molecular investigations involved using western blot, immunofluorescence, real-time PCR, RNA-seq analysis and chromatin immunoprecipitation.
Results
Based on our in-silico and immunohistochemistry analyses, HDAC6 levels are negatively correlated with PR status in breast cancer tissues. Chromatin immunoprecipitation (ChIP) assay demonstrated that HDAC6 enriched at the promoter site of the PGR-B gene in hormone receptor-positive and triple-negative breast cancer (TNBC) cells. The selective targeting of HDAC6 resulted in the enrichment of the H3K9 acetylation mark at the PGR-B gene promoter region and enhanced the expression of PR-B in both cells. Notably, the addition of HDAC6 inhibitor potentiated the effects of anti-ER and anti-PR drugs mainly in TNBC cells.
Conclusions
These data highlight the role of HDAC6 in regulating PR expression and provide a promising therapeutic approach for boosting breast cancer sensitivity to hormonal therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Sharjah.
Funding
Research Funding Department at the University of Sharjah [grant number 2101110354] and L'Oréal-UNESCO for Women in Science Middle East program [grant number 4500407531].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
82P - Applying computational approaches to build a predictive protein structure and discover novel inhibitors for mitotic serine/threonine kinase BUB1B
Presenter: Joan Glenny Pescov
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Development of a cell-free DNA scoring system from organoid culture medium to predict drug response in bladder cancer
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Quinacrine inhibits angiogenesis and migration of non-small cells lung cancer cells (NSCLC) by binding with the kinase domain of VEGFR2
Presenter: Angshuman Sarkar
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response
Presenter: Rhafaela Causin
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs)
Presenter: JUAN DIAZ ACOSTA
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma in multicellular spheroid model
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Clinical phenotyping of lung cancer-associated cachexia in relation to tumour volume in TRACERx
Presenter: Kexin Koh
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?
Presenter: Ramya Ramesh
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Prognostic value of tumor location and site-specific metastases in advanced biliary tract cancer
Presenter: Vanessa Patel
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract